01657nas a2200649   4500000000100000000000100001000000100002008004100003653001800044653001000062653001000072653000900082653001100091653001100102653002000113653002500133653002400158653002000182653002100202653001800223653004200241653001100283653001300294653002000307653002300327653002100350653002000371653002100391653005000412653004300462653001700505653001700522653001100539100001800550700001200568700001600580700001400596700001700610700001500627700001600642700001400658700001200672700001400684700001500698700001400713700001100727700001500738700001400753700001300767700001500780700001500795245013300810250001500943300001000958490000700968020003200975       2022                            d10aUnited States10aAdult10aChild10aMale10aHumans10aFemale10a*Celiac Disease10aLongitudinal Studies10aProspective Studies10a*Skin Neoplasms10aImmunoglobulin A10a*Osteoporosis10aRandomized Controlled Trials as Topic10aBiopsy10aChildren10aCoeliac disease10aCost-effectiveness10aDiagnostic tests10aEconomic models10aGluten-free diet10aImmunoglobulin a anti tissue transglutaminase10aImmunoglobulin a endomysial antibodies10aprimary care10aRisk Factors10aSurvey1 aM. Elwenspoek1 aH. Thom1 aA. Sheppard1 aE. Keeney1 aR. O'Donnell1 aJ. Jackson1 aC. Roadevin1 aS. Dawson1 aD. Lane1 aJ. Stubbs1 aH. Everitt1 aJ. Watson1 aA. Hay1 aP. Gillett1 aG. Robins1 aH. Jones1 aS. Mallett1 aP. Whiting00aDefining the optimum strategy for identifying adults and children with coeliac disease: systematic review and economic modelling  a2022/11/03  a1-3100 v26  a1366-5278 (Print)
1366-5278